NASDAQ: ENLV - Enlivex Therapeutics Ltd.

六个月盈利: -9.98%
部门: Healthcare

促销时间表 Enlivex Therapeutics Ltd.


关于公司

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd.

更多详情
is headquartered in Ness Ziona, Israel.

IPO date 1995-12-12
ISIN IL0011319527
Industry Software
Sector Information Technology
Валюта usd
Валюта отчета usd
Сайт https://www.enlivex.com
Цена ао 3.91
每日价格变化: -4.8% (1.25)
每周价格变化: -4.03% (1.24)
每月价格变化: +4.39% (1.14)
3个月内价格变化: -27.44% (1.64)
六个月内的价格变化: -9.98% (1.322)
每年价格变化: -55.93% (2.7)
3年内价格变化: -81.17% (6.32)
5年内价格变化: -84.86% (7.86)
10年价格变化: 0% (1.19)
年初以来价格变化: -4.8% (1.25)

低估

姓名 意义 年级
P/S 0 0
P/BV 1.8 8
P/E 0 0
EV/EBITDA -2.26 0
全部的: 3.5

效率

姓名 意义 年级
ROA, % -78.92 0
ROE, % -96.62 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0428 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -84.17 0
盈利能力 Ebitda, % 281.34 10
盈利能力 EPS, % 33.76 5
全部的: 7



导师 职称 支付 出生年份
Mr. Shai Novik M.B.A. Executive Chairman 528k 1966 (59 年)
Dr. Oren Hershkovitz Ph.D. Chief Executive Officer 273.6k 1977 (48 年)
Mr. Veronique Amor-Baroukh Senior Director of Operations N/A
Ms. Sigal Arad Director of HR N/A

地址: Israel, Ness Ziona, 14 Einstein Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.enlivex.com